SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 24, 2015
Date of Report
(Date of Earliest Event Reported)
CannaMED Enterprises, Inc.
(Exact Name of Registrant as Specified in its Charter)
REDWOOD VALLEY ACQUISITION CORPORATION
(Former Name of Registrant as Specified in its Charter)
Delaware 000-55308 47-2072746
(State or other (Commission File Number) (IRS Employer
jurisdiction Identification No.)
of incorporation)
391 East Brown Street
Stroudsburg, Pennsylavnia 19301
(Address of Principal Executive Offices)
(949) 673-4510
(Registrant's telephone number, including area code
ITEM 3.02 Unregistered Sales of Equity Securities
On August 25, 2015 CannaMED Enterprises, Inc. (formerly Redwood Valley
Acquisition Corporation) (the "Registrant" or the "Company") issued shares of
its common stock pursuant to Section 4(2) of the Securities Act of 1933 at par
representing 85.7% of the total outstanding 3,500,000 shares of common stock
as follows:
3,000,000 Mikhail J. Artamonov, MD
With the issuance of the stock and the redemption of 19,500,000 shares
of stock (discussed below), the Company effected a change in its control and
the new majority shareholder(s) elected new management of the Company. The
Company may develop its business plan by future acquisitions or mergers but
no agreements have been reached regarding any acquisition or other business
combination. If the Company makes any acquisitions, mergers or other business
combination, the Company will file a Form 8-K but until such time the Company
remains a shell company.
ITEM 5.01 Changes in Control of Registrant
On August 24, 2015, the following events occurred which resulted in a
change of control of the Registrant:
1. The Registrant redeemed an aggregate of 19,500,000 of the then
20,000,000 shares of outstanding stock at a redemption price of $.0001
per share for an aggregate redemption price of $1,950.
2. The then current officers and directors resigned.
3. New officer(s) and director(s) were appointed and elected.
The disclosure required by Item 5.01(a)(8) of Form 8-K was previously
filed with the Securities and Exchange Commission on Form 10-12G filed on
November 11, 2014 as amended and supplemented by the information contained
in this report.
The Registrant intends to consult with or effect a business combination
with a private company to develop as medical cannabis industry innovators,
utilizing the Company's team of healthcare and business professionals to start
and/or source, research, evaluate and purchase products and companies. The
Company will strive to develop environmentally friendly and economically
sustainable business within the swiftly developing medical cannabis industry.
The Company envisions to initially enter into joint ventures or acquire
partial ownership in:
a laboratory for medical cannabis testing, a pharmacy to perform research;
a pharmacy to perform research and development of the newest medical
cannabis formulations;
a clinical practice to establish the network dispensaries;
a packaging company;
a research facility; and
real estate to establish the foundation for the growing network
ITEM 5.02 Departure of Directors or Principal Officers;
Election of Directors
On August 24, 2015 James M. Cassidy resigned as the Registrant's president,
secretary and director and James McKillop resigned as the Registrant's vice
president and director.
On August 24, 2015, Mikhail J. Artamonov, MD, was elected director of the
Registrant and appointed to serve as President, Secretary, and Treasurer of
the Registrant.
Mikhail J. Artamonov, MD, serves as the sole officer and director of the
Registrant. Dr. Artamonv received his M.D. in General Medicine from the 1st
Moscow Medical Sechenov School, Russia in 1994 and was a resident in the
Combined Residency Training Program for Rehabilitation, Pain and Complementary
Medicine from 1994 to 1997 at the 1st Moscow Medical Sechenov School, Russia
and Hanover Medical University, Germany. From 1997 to 1999, Dr. Artamonov was
a clinical and research fellow in psychotherapy at the 1st Moscow Medical
Sechenov School, Russia and from 1999 to 2000 was at the Internship Training
Program in Internal Redicine-Primary Care at the Brooklyn Jewish Hospital,
New York. From 2000 to 2003 Dr. Artamonov was in the Residency Training
Program for Physical Medicine and Rehabilitation at Temple University and
from 2003 to 2004, Dr. Artamonov was a Clinical Fellow at the Harvard Medical
School Combined Pain Fellowship and working in Acute, Chronic and Cancer Pain
in Adults and Children at Brigham and Women's Hospital, Boston, Beth Israel
Deaconess Medical Center, Boston, Boston Children's Hospital and Dana Farber's
Cancer Center, Boston. From 2009 to 2014, Dr. Aramonov was an Advanced Fellow
in the Fellowship in Anti-Aging, Regenerative & Functional Medicine. From 2011
to the present, Dr. Artamonov has served as CEO and President of MJA Healthcare
Network, a multispecialty healthcare system consisting of over 15 entities.
Dr. Artamonov is Board Certified in Brain Injury Medicine, Anti-Aging and
Functional Medicine, and Pain Medicine. Dr. Artamonov has published books
including "Pot Luck: Why Marijuana is Today's Medicine" (2015), "Integrative
Interventional Pain Management" (2014), "Your Health, Your Weight, Your Life"
(2012) and "Health is Everything: Patients, Practitioners and Good Medicine"
(2011).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunder duly authorized.
CANNAMED ENTERPRISES, INC.
/s/ Mikhail J. Artamonov
President
Date: August 26, 201
